Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 4/20 | 0.34 |
| ▸ | NOS2 | P35228 | 4/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14202550 | 0.75 | — | — | |
| SCHEMBL7813061 | 0.75 | — | — | |
| SCHEMBL8371411 | 0.75 | LOXL2 (0.32) | — | |
| SCHEMBL4065234 | 0.75 | CHEK1 (0.42) | — | |
| SCHEMBL12899438 | 0.75 | HSP90AA1 (0.31) | — | |
| SCHEMBL8374289 | 0.72 | HPGD (0.42) | SMN1; SMN2 | |
| SCHEMBL17537338 | 0.71 | CYP2A6 (0.41) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7814813 | 0.71 | — | — | |
| SCHEMBL13454732 | 0.70 | CCR1 (0.38) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL13454694 | 0.70 | LMNA (0.30) | CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-29 | — | — | US | disclosed |
| US-20220289739-A1 | SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2022-09-15 | — | — | US | disclosed |
| US-11427580-B2 | 6-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210403468-A1 | SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210393608-A1 | SUBSTITUTED INDOLE DIMER COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-23 | — | — | US | disclosed |
| US-20200385382-A1 | 6-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-10 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-8530652-B2 | Pyrrolopyrazoles, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8426585-B2 | Compounds comprising a spiro-ring | Xi, Ning (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120283296-A1 | PYRROLOPYRAZOLES FOR TREATING CNS DISORDERS | AFRAXIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120264751-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2012-10-18 | — | — | US | disclosed |
| WO-2006000085-A1 | HEPATITIS C INHIBITOR PEPTIDE ANALOGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | CCR1 1871/4885CCR5 3381/4885CCR8 1958/4885 |
| US-20210393608-A1 | SUBSTITUTED INDOLE DIMER COMPOUNDS | TLR7, TLR9, NOD2 | CCR1 389/4885CCR5 429/4885CCR8 262/4885 |
| US-20120283296-A1 | PYRROLOPYRAZOLES FOR TREATING CNS DISORDERS | PAK2, PAK3, PAK5 | CCR1 1174/4885CCR5 1394/4885CCR8 1094/4885 |
| US-20120264751-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | CCR1 3717/4885CCR5 2978/4885CCR8 3794/4885 |
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | CCR1 788/4885CCR5 494/4885CCR8 1701/4885 |
| US-20200385382-A1 | 6-AZAINDOLE COMPOUNDS | TLR7, TLR9, TLR5 | CCR1 310/4885CCR5 204/4885CCR8 188/4885 |
| US-11427580-B2 | 6-azaindole compounds | TLR7, TLR9, TLR5 | CCR1 310/4885CCR5 204/4885CCR8 188/4885 |
| US-20220289739-A1 | SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS | TLR7, TLR1, TLR9 | CCR1 215/4885CCR5 249/4885CCR8 174/4885 |
| US-20210403468-A1 | SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS | TLR1, TLR7, IDO1 | CCR1 59/4885CCR5 217/4885CCR8 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.